Why the study?
Stringent variant interpretation guidelines lead to high rates of variants of uncertain significance for genetically heterogeneous diseases like LQTS and BrS, which quantitative and disease-specific customization of ACMG/AMP guidelines could address.
Does quantitative and disease-specific customization of ACMG/AMP guidelines improve diagnostic yield and reduce VUS in inherited arrhythmias?
Does quantitative and disease-specific customization of ACMG/AMP guidelines improve diagnostic yield and reduce VUS in inherited arrhythmias?
Disease-specific customization of ACMG/AMP guidelines using large case-control datasets significantly improves diagnostic yield and reduces variants of uncertain significance in inherited arrhythmias.
Customized ACMG/AMP rules may raise diagnostic yield in LQTS/BrS testing; supports quantitative case-control customization but leaves open prospective validation.
PURPOSE: Stringent variant interpretation guidelines can lead to high rates of variants of uncertain significance (VUS) for genetically heterogeneous disease like long QT syndrome (LQTS) and Brugada syndrome (BrS). Quantitative and disease-specific customization of American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) guidelines can address this false negative rate. METHODS: We compared rare variant frequencies from 1847 LQTS (KCNQ1/KCNH2/SCN5A) and 3335 BrS (SCN5A) cases from the International LQTS/BrS Genetics Consortia to population-specific gnomAD data and developed disease-specific criteria for ACMG/AMP evidence classes-rarity (PM2/BS1 rules) and case enrichment of individual (PS4) and domain-specific (PM1) variants. RESULTS: ). Ion channel transmembrane regions and specific N-terminus (KCNH2) and C-terminus (KCNQ1/KCNH2) domains were characterized by high enrichment of case variants and >95% probability of pathogenicity. Applying the customized rules, 17.4% of European BrS and 74.8% of European LQTS cases had (likely) pathogenic variants, compared with estimated diagnostic yields (case excess over gnomAD) of 19.2%/82.1%, reducing VUS prevalence to close to background rare variant frequency. CONCLUSION: Large case-control data sets enable quantitative implementation of ACMG/AMP guidelines and increased sensitivity for inherited arrhythmia genetic testing.
No takes yet. Share an insight, caveat, or question.
Walsh et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: